OBJECTIVE:: The efficacy of docetaxel has recently been shown to be increased under
hypoxic conditions through the down-regulation of hypoxia-inducible-factor 1α (HIF1A) …

Purpose: To understand the role of hypoxia in prostate tumor progression and to evaluate
the ability of the novel unidirectional hypoxia-activated prodrug OCT1002 to enhance the …

Prostate cancer (PCa) has a high incidence worldwide. One of the major causes of PCa
resistance is intratumoral hypoxia. In solid tumors, hypoxia is strongly associated with …

Prostate cancer is the second most frequently diagnosed cancer worldwide. Hypoxia‐
induced epithelial–mesenchymal transition (EMT), driven by hypoxia‐inducible factor 1α …

Nitric oxide‐donating non‐steroidal anti‐inflammatory drugs are safer than traditional
NSAIDs and inhibit the growth of prostate cancer cells with greater potency than NSAIDs. In …

Predicting and treating recurrence in intermediate-risk prostate cancer patients remains a
challenge despite having identified genomic instability and hypoxia [,] as risk factors. This …

Background OCT1002 is a unidirectional hypoxia‐activated prodrug (uHAP) OCT1002 that
can target hypoxic tumor cells. Hypoxia is a common feature in prostate tumors and is known …

Paclitaxel (PTX) is an anticancer drug that is effective against a wide range of solid tumors.
The effect of PTX on two human lung cancer cell lines, PC14PE6 and NCI‐H441 cells, was …

Background: Histone deacetylase inhibitors (HDACis) like vorinostat are promising
radiosensitisers in prostate cancer, but their effect under hypoxia is not known. We …

Tumor cell hypoxia is an innate environmental factor encountered during the development of
many types of human tumors, including malignant prostate tumors. For prostate cancer …